Home Ablative Solutions Inc.

Ablative Solutions Inc.

    Ablative Solutions Announces $77 Million Financing for Unique Therapeutic Approach to Treating Uncontrolled Hypertension

    1/3/19: The company pioneering new approaches for the treatment of hypertension. Today the company announced the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors including Michigan Accelerator Fund, Novus Biotechnology and other individual investors also participated the Series D funding round.

    RECENT COMMENTS